Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk
- First Online:
- 65 Downloads
Prostate-specific antigen (PSA) is a tumor marker helpful in the diagnosis and follow-up of prostate cancer. However, PSA level may rise due to other causes than prostate cancer such as benign prostatic hyperplasia (BPH), acute prostatitis, chronic bacteria and a bacterial prostatitis. Total serum PSA (TPSA) and free prostate-specific antigen (FPSA) levels of patients with prostatitis symptoms as well as these levels in male population at risk but without clinical prostatic diseases (>40-years-old) with regard to age should be documented in order to increase the sensitivity and specificity of PSA in prostate carcinoma.
A comprehensive urological examination was performed on 1150 male patients over the age of 40 with prostatism symptoms from the random-sample community based in with no diagnostic prostate cancer. Men with PSA level 4.1 ng/ml or greater were referred for biopsy and those with positive biopsies or with medical record, cancer registry, or self-reported evidence of prostate cancer were excluded. Data were studied as a function of age to determine the usefulness of measuring TPSA and FPSA as screening tests for risk patient’s cancer.
Because of the greater variability at older ages, the 95th percentile increased faster than the median, the following age-specific reference ranges of TPSA and FPSA for patients with prostatism symptoms were as follows: 3.1 and 0.7 ng/ml for the age group 40–49 years, 4.4 and 0.89 ng/ml for the age group 50–59 years, 5.6 and 1.3 ng/ml for the age group 60–69 years, and 6.3 and 1.8 ng/ml for age group 70–79 years. There was a continuous increase in TPSA and FPSA means and medians with significant correlation (P < 0.001, P < 0.005) and advancing age group. The aim of this study was to find out age-specific values and ranges of TPSA and FPSA in patients with prostatism symptoms to ensure low false-positive biopsy rates.
KeywordsSpecific reference ranges Total-, Free prostate-specific antigen and their ratio Prostatitis Prostatism
Unable to display preview. Download preview PDF.
- 1.Nixon RG, Lilly JD, Liedtke RJ, Batjer JD (1997) Variation of free and total prostate-specific antigen levels: the effect on the percent free/total-specific antigen. Arch Pathol Lab Med Northfield 121(4):385–387Google Scholar
- 3.Oestrling JE (1991) Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907–923Google Scholar
- 10.Walsh PC (1993) Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann intern Med 119:984–949Google Scholar
- 13.Sershon PD, Barry MJ, Oestrling JE (1993) Serum PSA values in men with histologically confirmed BPH versus patients with organ-confined prostate cancer (abstract.). J␣Urol 149:421AGoogle Scholar
- 15.Oestrerling JE, Chute CG (1993) Longitudinal changes in serum PSA (PSA velocity) in a community-based cohort of men (Abstract). J Urol 149:412AGoogle Scholar
- 23.Niederau ChM, Beyrau R, Gurr E, Neumeier D, Peisker K, Raith H, Wood P, Domke I (1998) External evaluation of tumor markers on elesys 1010 immunoanalyzer. Tumor Marker Oncol 13(2):29–30Google Scholar
- 24.Steel RG, Torrie JH (1980) Principle and procedures of statistics. McGraw-Hill Book Co, New YorkGoogle Scholar
- 26.Seamean E, Katz A (1993) An algorithm for prostate cancer detection based upon PSA TRUS, DRE, PSA density, and PSA velocity (Abstract). J Urol 149:414AGoogle Scholar
- 28.Dalkin L, Ahman F (1993) Derivation of normal prostate specific antigen (PSA) level by age (Abstract). J Urol 149:413AGoogle Scholar
- 30.Crawford ED (1993) Report on the 1992 Prostate Cancer Awareness Week (Abstract). J Urol 149:55AGoogle Scholar
- 34.Battikhi MN, Hussein I Serum prostate-specific antigen (PSA) in men without clinical evidence of prostate cancer. J Tumor Oncol Marker (In Press) Google Scholar